We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Pathogenic Antibodies Decline Over Time in VITT

By LabMedica International staff writers
Posted on 25 Sep 2021
Vaccine-induced immune thrombotic thrombocytopenia (VITT) has been described after vaccination with the adenoviral vector vaccines. More...
A syndrome characterized by venous or arterial thrombosis, particularly at unusual sites including cerebral sinus venous thrombosis (CSVT)/splanchnic thrombosis, and mild to severe thrombocytopenia.

VITT is caused by platelet-activating anti–platelet factor 4 (PF4) IgG antibodies, the presence of which can be confirmed by anti–PF4–heparin IgG enzyme-linked immunosorbent assay (ELISA) in combination with PF4-enhanced washed-platelet–activation assays. Clinical and in vitro characteristics of acute VITT closely resemble (autoimmune) heparin-induced thrombocytopenia.

Medical Scientists at the Universitätsmedizin Greifswald (Greifswald, Germany) conducted a study involving 35 patients with serologically confirmed VITT (27 women and eight men; median age, 53 years [range, 18 to 77 years]). The patients’ clinical symptoms started between days five and 18 after vaccination. All the patients presented with thrombocytopenia, and 30 presented with thrombosis.

Anti-PF4 IgG antibodies were tested by PF4/heparin ELISA. The cut-off of the ELISA was defined as optical density (OD) 0.5; samples testing >0.5 - 1.0 were defined as positive, between >1.0 - 2.0 as strongly–positive; greater 2.0 OD were defined as very strongly positive. Platelet activation by the antibodies was tested in a PF4-dependent washed platelet assay. Negatively tested sera were repeated with a new panel of washed platelets on a different day. A positive result was defined as PF4-dependent activation of platelets (lag time, <30 min) of at least two of three different donors.

The scientists reported that results of the PF4-dependent platelet-activation assay became negative in 23 of 35 patients (66%). In 14 of the 15 patients (93%), with follow-up of more than 12 weeks the platelet-activation assay became negative within a median of 12 weeks. In addition, the median optical density on anti–PF4–heparin IgG ELISA declined by 53% between the first and last available blood samples (median optical density, 2.98 versus 1.39). However, full seroreversion to a negative ELISA result (i.e., an optical density of <0.5) was seen in only three patients. In one patient, PF4-dependent platelet-activating antibodies and ELISA optical density values of greater than 3.0 persisted for more than 12 weeks in association with recurrent episodes of thrombocytopenia.

The authors reported that to achieve full protection against coronavirus disease 2019 (Covid-19), a second vaccination is needed after a first dose of ChAdOx1 nCoV-19. On the basis of their small series of patients, subsequent vaccination with an mRNA vaccine appears to be safe after results of platelet-activation assays for VITT antibodies have become negative. When no platelet-activation assay is available, a substantial decline in the optical density on anti–PF4–heparin IgG ELISA may be used as a decision criterion. The study was published on September 8, 2021 in The New England Journal of Medicine.

Related Links:

Universitätsmedizin Greifswald


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.